DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis
USA - NASDAQ:DARE - US23666P2002 - Common Stock
2.03 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to DARE. DARE was compared to 192 industry peers in the Pharmaceuticals industry. DARE has a bad profitability rating. Also its financial health evaluation is rather negative. DARE has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year DARE has reported negative net income.
In the past year DARE had a positive cash flow from operations.
In the past 5 years DARE always reported negative net income.
DARE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of DARE (-9.00%) is better than 67.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DARE has a Gross Margin of 108.60%. This is amongst the best in the industry. DARE outperforms 98.96% of its industry peers.
DARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 108.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DARE has more shares outstanding
The number of shares outstanding for DARE has been reduced compared to 5 years ago.
The debt/assets ratio for DARE is higher compared to a year ago.
2.2 Solvency
DARE has an Altman-Z score of -17.43. This is a bad value and indicates that DARE is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.43, DARE is doing worse than 80.21% of the companies in the same industry.
DARE has a debt to FCF ratio of 1.20. This is a very positive value and a sign of high solvency as it would only need 1.20 years to pay back of all of its debts.
DARE has a better Debt to FCF ratio (1.20) than 94.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.2 | ||
| Altman-Z | -17.43 |
ROIC/WACCN/A
WACC8.6%
2.3 Liquidity
A Current Ratio of 0.56 indicates that DARE may have some problems paying its short term obligations.
DARE has a Current ratio of 0.56. This is amonst the worse of the industry: DARE underperforms 91.15% of its industry peers.
DARE has a Quick Ratio of 0.56. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
DARE's Quick ratio of 0.56 is on the low side compared to the rest of the industry. DARE is outperformed by 90.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.56 |
3. Growth
3.1 Past
DARE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -91.96%.
Looking at the last year, DARE shows a very negative growth in Revenue. The Revenue has decreased by -99.65% in the last year.
EPS 1Y (TTM)-91.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.61%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-195.45%
3.2 Future
Based on estimates for the next years, DARE will show a very strong growth in Earnings Per Share. The EPS will grow by 70.66% on average per year.
DARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 188.14% yearly.
EPS Next Y-204.04%
EPS Next 2Y57.81%
EPS Next 3Y81.13%
EPS Next 5Y70.66%
Revenue Next Year-61.82%
Revenue Next 2Y392.65%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
DARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 7.96 indicates a rather cheap valuation of DARE.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DARE indicates a rather cheap valuation: DARE is cheaper than 89.06% of the companies listed in the same industry.
DARE is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.96 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DARE indicates a rather cheap valuation: DARE is cheaper than 96.88% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.55 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DARE's earnings are expected to grow with 81.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.81%
EPS Next 3Y81.13%
5. Dividend
5.1 Amount
No dividends for DARE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:DARE (10/28/2025, 8:00:01 PM)
2.03
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.71%
Inst Owner Change-1.87%
Ins Owners0.75%
Ins Owner Change0%
Market Cap27.36M
Revenue(TTM)9.80K
Net Income(TTM)-1676500
Analysts82
Price Target10.97 (440.39%)
Short Float %1.55%
Short Ratio1.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-19.49%
Max EPS beat(2)15.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.2%
Min Revenue beat(2)-104.71%
Max Revenue beat(2)-91.69%
Revenue beat(4)0
Avg Revenue beat(4)-99.03%
Min Revenue beat(4)-104.71%
Max Revenue beat(4)-91.69%
Revenue beat(8)1
Avg Revenue beat(8)-58.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-17.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11%
EPS NY rev (1m)0%
EPS NY rev (3m)21.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-21%
Revenue NY rev (3m)-92.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.96 | ||
| P/S | 305.75 | ||
| P/FCF | 4.55 | ||
| P/OCF | 4.06 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.15
EYN/A
EPS(NY)0.26
Fwd EY12.56%
FCF(TTM)0.45
FCFY21.98%
OCF(TTM)0.5
OCFY24.62%
SpS0.01
BVpS-0.71
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 108.6% | ||
| FCFM | 6719.11% |
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.2 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 381.33% | ||
| Cap/Sales | 807.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.56 | ||
| Altman-Z | -17.43 |
F-Score3
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.61%
EPS Next Y-204.04%
EPS Next 2Y57.81%
EPS Next 3Y81.13%
EPS Next 5Y70.66%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-195.45%
Revenue Next Year-61.82%
Revenue Next 2Y392.65%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y127.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.8%
OCF growth 3YN/A
OCF growth 5YN/A
DARE BIOSCIENCE INC / DARE FAQ
Can you provide the ChartMill fundamental rating for DARE BIOSCIENCE INC?
ChartMill assigns a fundamental rating of 3 / 10 to DARE.
What is the valuation status of DARE BIOSCIENCE INC (DARE) stock?
ChartMill assigns a valuation rating of 5 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Fairly Valued.
Can you provide the profitability details for DARE BIOSCIENCE INC?
DARE BIOSCIENCE INC (DARE) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for DARE stock?
The Earnings per Share (EPS) of DARE BIOSCIENCE INC (DARE) is expected to decline by -204.04% in the next year.